Pembrolizumab for second line treatment of advanced hepatocellular carcinoma—who would benefit?
@article{CCO111266,
author = {Morten Ladekarl},
title = {Pembrolizumab for second line treatment of advanced hepatocellular carcinoma—who would benefit?},
journal = {Chinese Clinical Oncology},
volume = {12},
number = {2},
year = {2023},
keywords = {},
abstract = {},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/111266}
}